Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Clorazepic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | ALB | P02768 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.65 |
| ▸ | CCKBR | P32239 | 4/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clorazepic Acid SCHEMBL34618 | 1.00 | LMNA (0.73) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL1649064 | 1.00 | LMNA (0.73) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL29484725 | 1.00 | LMNA (0.73) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL27617141 | 0.99 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL1302660 | 0.99 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL9694061 | 0.99 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL4287456 | 0.99 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL236792 | 0.99 | LMNA (0.72) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL29374553 | 0.98 | LMNA (0.70) | LMNAMEN1ALBKMT2ACHRM1 | |
| Clorazepic Acid SCHEMBL21462311 | 0.98 | LMNA (0.70) | LMNAMEN1ALBKMT2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18083 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-12594256-B2 | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2026-04-07 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260076953-A1 | METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-19 | — | — | US | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| EP-0216555-A2 | Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections | BTG INTERNATIONAL LIMITED (GB) | 1987-04-01 | — | — | EP | claimed |
| EP-0196002-A2 | Tablet composition for drug combinations | ABBOTT LABORATORIES (US) | 1986-10-01 | — | — | EP | claimed |
| EP-0098113-B1 | A COMBINATION OF BETA-ADRENOCEPTOR ANTAGONISTS AND ANXIOLYTIC AGENTS | AYERST, MCKENNA AND HARRISON INC. (CA) | 1986-09-03 | — | — | EP | claimed |
| US-4595684-A | Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof | CIBA-GEIGY CORPORATION (US) | 1986-06-17 | — | — | US | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| EP-0098113-A1 | A combination of beta-adrenoceptor antagonists and anxiolytic agents | AYERST, MCKENNA AND HARRISON INC. (CA) | 1984-01-11 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
| US-4028466-A | Analgesic compositions comprising dextro-propoxyphene and benzodiazepine and process | BERGER FRANK M | 1977-06-07 | — | — | US | claimed |
| US-4028467-A | Analgesic compositions comprising levo-propoxyphene and benzo diazepine and process | BERGER FRANK M | 1977-06-07 | — | — | US | claimed |